baicalein (a lipoxygenases inhibitor) (1.2 µmol/animal) had no effect.
widespread throughout the brain. 6 It has been shown that intravenous and intracerebroventricular administration of GLP-1 receptor agonists increases blood pressure and heart rate and induces c-Fos-like immunoreactivity in autonomic regulatory neurons in the brain. [7] [8] [9] These observations suggest a role for GLP-1 in the regulation of several autonomic responses in the brain. 10 However, the central mechanisms underlying these actions of GLP-1 remain largely undefined.
Previously, we reported that intracerebroventricular pretreatment with indomethacin, an inhibitor of cyclooxygenase, effectively reduced the increase of plasma noradrenaline and adrenaline induced by intracerebroventricularly (i.c.v.)-administered corticotrophin-releasing factor (CRF), 11 arginine-vasopressin, 12 and bombesin. 13, 14 These results suggest the involvement of brain prostanoids in the central activation of the sympatho-adrenomedullary outflow in rats. In the present study, therefore, we investigated the mechanisms involved in i.c.v.-administered GLP-1-induced elevation of plasma catecholamines with regard to the brain prostanoids in urethane-anesthetized rats. 
METHODS

Experimental procedures
Male Wistar rats weighing approximately 350 g were maintained in an air-conditioned room at 22-24ºC under a constant day-night rhythm for more than 2 weeks and given food (laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and water ad libitum. With the rats under urethane anesthesia (1.0 g/kg, i.p.), the femoral vein was cannulated for infusion of saline (1.2 mL/h), and the femoral artery was cannulated for collecting blood samples, as described previously. 15 For some animals, acute bilateral adrenalectomy (plus hydrocortisone 5 mg/kg, i.m.) or a sham operation (plus 200 µL saline/animal, i.m.) 16 was carried out just before the experiments through bilateral dorsal incisions using an aseptic surgical technique.
Next, the animal was placed in a stereotaxic apparatus, as described previously. All experiments were conducted in compliance with the guiding principles for the care and use of laboratory animals approved by Kochi University. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Measurement of plasma catecholamines
Blood samples (250 µL) were collected through an arterial catheter and preserved on ice during the experiments. Plasma was prepared immediately after the final sampling.
Catecholamines in the plasma were extracted by the method of Anton and Sayre, 18 with a slight modification, and were assayed electrochemically with high-performance liquid chromatography (HPLC). 15 Briefly, after centrifugation, plasma (100 µL) was transferred to a sample tube containing 30 mg of activated alumina, 1 ng of 3,4-dihydroxybenzylamine as an internal standard, and 3 mL of 0.5 M Tris buffer (pH 8.6) containing 0.1 M disodium EDTA. The tube was shaken for 10 min, and the alumina was washed three times with 4 mL of ice-cold, double-deionized water. Then, the catecholamines adsorbed onto the alumina were eluted with 300 µL of 4% acetic acid containing 0.1 mM disodium EDTA.
A pump (EP-300: Eicom, Kyoto, Japan), a sample injector (Model-231XL; Gilson, Villiers-le-Bel, France), and an electrochemical detector (ECD-300: Eicom) equipped with a graphite electrode were used with HPLC. Analytical conditions were as follows:
detector +450 mV potential against an Ag/AgCl reference electrode; column, Eicompack CA-50DS, 2.1 x 150 mm (Eicom); mobile phase, 0.1 M NaH 2 PO 4 -Na 2 HPO 4 buffer (pH 6.0) containing 50 mg/L disodium EDTA, 750 mg/L 1-octane sulfate sodium (Nacalai Tesque, Kyoto, Japan) and 15% methanol, at a flow rate of 0.18 mL/min. The amount of catecholamines in each sample was calculated using the peak height ratio relative to that of 3,4-dihydroxybenzylamine. This assay could determine 0.5 pg of noradrenaline and adrenaline accurately.
Treatment of data and statistics
Results are expressed as the mean±S.E.M. of the net change above the respective basal values. The data were analyzed by repeated-measure analysis of variance (ANOVA), followed by post-hoc analysis with the Bonferroni method for comparing a control to all other means (Figs. 1, 2 and 4B). When only two means were compared, the data were Ltd. (Osaka, Japan), respectively. All other reagents were purchased from Nacalai
Tesque (Kyoto, Japan). 
RESULTS
Effect of GLP-1 on the plasma levels of catecholamines
Administration of vehicle (5 µL of saline/animal) and blood sampling five times over a 60-min period had no effect on the basal plasma levels of either noradrenaline or adrenaline ( Fig. 1 ).
GLP-1 dose-dependently elevated plasma levels of noradrenaline and adrenaline ( 
Effect of exendin (5-39) on the GLP-1-induced elevation of plasma catecholamines
Pretreatment with exendin (5-39) (a GLP-1 receptor antagonist) (10 nmol/animal) had no effect on the basal plasma levels of noradrenaline and adrenaline ( 
Effects of indomethacin and baicalein on the GLP-1-induced elevation of plasma catecholamines
Effects of furegrelate and (+) S-145 on the GLP-1-induced elevation of plasma catecholamines
Pretreatment with furegrelate (a thromboxane A 2 synthase inhibitor) (1.8 µmol [500 µg]/animal) had no effect on the basal plasma levels of noradrenaline and adrenaline (Fig.   4A ). Pretreatment with furegrelate significantly reduced the elevation of adrenaline induced by GLP-1 (1.0 nmol/animal), but the reagent had no effect on the elevation of noradrenaline induced by this peptide (Fig. 4A ).
According to our previous report, 14 we used (+) S-145 (a thromboxane A 2 receptor antagonist) at doses of 250 and 625 nmol/animal in the present experiment (Fig. 4B ).
Pretreatment with this reagent (625 nmol/animal) had no effect on the basal plasma levels of noradrenaline and adrenaline. Pretreatment with this reagent effectively attenuated the GLP-1 (1.0 nmol/animal)-induced elevation of adrenaline in a dose-dependent manner (250 and 625 nmol/animal), while it slightly, but not significantly, reduced the elevation of noradrenaline induced by this peptide (Fig. 4B) .
Effect of bilateral adrenalectomy on the GLP-1-induced elevation of plasma catecholamines
The basal plasma levels of noradrenaline and adrenaline were reduced slightly by sham operation. The basal plasma level of noradrenaline was reduced slightly, but not significantly, by bilateral adrenalectomy, while the basal plasma level of adrenaline was reduced significantly by the procedure (Fig. 5 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The GLP-1 (1.0 nmol/animal)-induced elevation of plasma adrenaline was abolished by bilateral adrenalectomy, while the procedure had no effect on the peptide-induced elevation of plasma noradrenaline (Fig. 5 ).
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Clinical and Experimental Pharmacology and Physiology Previously, we reported that the brain cyclooxygenase is involved in centrally administered CRF-, arginine-vasopressin-, and bombesin-induced elevations of plasma noradrenaline and adrenaline using indomethacin in rats. 11, 12, 13 The elevation of plasma noradrenaline induced by centrally administered interleukin-1ß was also attenuated by central pretreatment with indomethacin. 22 Since indomethacin is a potent inhibitor of the prostaglandin-forming cyclooxygenase, 23 active products of cyclooxygenase seem to be involved in the elevations of plasma catecholamines induced by these peptides in rats.
However, it remains possible that active products of the brain lipoxygenases are involved in the elevations of plasma catecholamines induced by these peptides.
In the next experiment, therefore, we examined the effects of centrally administered 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In general, plasma noradrenaline reflects the activity of the sympathetic nervous system, while plasma adrenaline reflects the activity of the adrenomedullary system.
Recently, we demonstrated that centrally administered arginine-vasopressin, bombesin and histamine elicit adrenal secretion of both noradrenaline and adrenaline by brain thromboxane A 2 -mediated mechamisms, while centrally administered CRF elicits sympathetic noradrenaline release and adrenal adrenaline secretion by brain prostaglandin E 2 -and thromboxane A 2 -mediated mechanisms, respectively, in rats. [14] [15] [16] Furthermore, it has been reported that noradrenaline-containing cells and adrenaline-containing cells in the adrenal medulla are innervated separately by preganglionic neurons in the spinal cord. 27 More recently, using c-Fos expression, we demonstrated that adrenaline-and noradrenaline-containing cells in the adrenal medulla and celiac sympathetic ganglia are differentially controlled by brain thromboxane A 2 and prostanoids other than thromboxane A 2 (probably prostaglandin E 2 ), respectively, in rats. 28 In the last experiment, we performed acute bilateral adrenalectomy to determine the origin of plasma catecholamines induced by centrally administered GLP-1. Bilateral adrenalectomy abolished the centrally administered GLP-1-induced elevation of plasma adrenaline, while the procedure had no effect on the elevation of plasma noradrenaline.
These results suggest that centrally administered GLP-1 evokes noradrenaline release from sympathetic nerves and adrenaline secretion from the adrenal gland in rats.
GLP-1-containing nerve terminals densely innervate neurons in the hypothalamic paraventricular nucleus, 29 which has been recognized as a regulatory center of the sympatho-adrenomedullary system. 30 These observations further support the present 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 and 99±17 and 52±6 pg/mL in the bilateral adrenalectomized group (n = 5), respectively.
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